References
- Li FP, Fraumeni JF, Jr. Soft-tissue sarcomas, breast cancer, and other
neoplasms. A familial syndrome? Ann Intern Med. 1969;71(4):747-752.
- Ko LJ, Prives C. p53: Puzzle and Paradigm. Genes Dev.
1996;10(9):1054-1072.
- Levine AJ. p53, the cellular gatekeeper for growth and division. Cell.
1997;88(3):323‐331.
- Hwang S-J, Lozano G, Amos CI, Strong LC. Germline p53 mutations in a
cohort with childhood sarcoma: Sex differences in cancer risk. Am J
Hum Genet. 2003;72(4):975-983.
- Malkin D, Li FP, Strong LC, Fraumeni JFJ, Nelson CE, Kim DH, Kassel J,
Gryka MA, Bischoff FZ, Tainsky MA. 1990. Germ line p53 mutations in a
familial syndrome of breast cancer, sarcomas, and other neoplasms.
Science. 250:1233–1238.
- Mai PL, Best AF, Peters JA, DeCastro RM, Khincha PP, Loud JT, et al.
Risks of first and subsequent cancers among TP53 mutation carriers in
the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer.
2016;122(23):3673-3681.
- Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional
properties on TP53 mutation patterns and tumor phenotype: lessons from
recent developments in the IARC TP53 database. Hum Mutat .
2007;28(6):622‐629.
- Rieber J, Remke M, Hartmann C, Korshunov A, Burkhardt B, Sturm D, et
al. Novel Oncogene Amplifications in Tumors from a Family with
Li-Fraumeni Syndrome. Genes, Chromosomes & Cancer.
2009;48(7):558-568.
- Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, et al.
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance
Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With
Resectable High-Grade Osteosarcoma and Good Histologic Response to
Preoperative MAP: First Results of the EURAMOS-1 Good Response
Randomized Controlled Trial. J Clin Oncol. 2015; 33(20):2279-87.
- Living LFS. c2015-2020 [cited 2020 May 31]. Li-Fraumeni Education
and Early Detection Program (LEAD). Available from
www.livinglfs.org/wp-content/uploads/2016/03/LEAD-Pediatric-screening-program-2016.pdf.
- Bojadzjeva J, Behrang A, Day S F, Jackson TL, Thomas PS, Willis BJ, et
al. Whole body magnetic imaging ( WB-MRI) and brain MRI baseline
surveillance in TP53 germline mutation carriers: experience from the
Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic.
Familial Cancer. 2018; 17(2):287-294.
- Mata-Mbemba D, Zapotocky M, Laughlin S, Taylor MD, Ramaswamy V,
Raybaud C. MRI Characteristics of Primary Tumors and Metastatic
Lesions in Molecular Subgroups of Pediatric Medulloblastoma: A
Single-Center Study. Am J Neuroradiol. 2018; 39(5): 945-955.
- Koral K, Zhang S, Gargan L, Moore W, Garvey B, Fiesta M, et al.
Diffusion MRI Improves the Accuracy of Preoperative Diagnosis of
Common Pediatric Cerebellar Tumors among Reviewers with Different
Experience Levels. Am J Neuroradiol. 2013; 34(12):2360-2365.
- The International Agency for Research on Cancer. WHO Classification of
Tumours of the Central Nervous System. Revised 4thed. Lyon: World Health Organization; 2016. p. 190.
- Villani A, Tabori U, Schiffman J, Shlien A, Beyene J, Druker H, et al.
Biochemical and imaging surveillance in germline TP53 mutation
carriers with Li-Fraumeni syndrome: a prospective observational study.
Lancet Oncol. 2011; 12(6):559-567.
- Villani A, Tabori U, Shore A, Wasserman JD, Stephens D, Kim RH, et al.
Biochemical and imaging surveillance in germline TP53 mutation
carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective
observational study. Lancet Oncol. 2016; 17(9):1295-1305.
- Yeom KW, Mobley BC, Lober
RM, Andre
JB, Partap S, Vogel H, et al. Distinctive MRI Features of Pediatric
Medulloblastoma Subtypes. American Journal of
Roentgenol. 2013; 200(4): 895-903.